An observational study in Kidney Cancer, sponsored by University Hospital, Bordeaux. Recruiting at 68 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by University Hospital, Bordeaux · Observational
Kidney cancer management has become increasingly complex with the diversification of treatment options and the integration of multidisciplinary care. To meet these challenges, the UroCCR network was established in France as a national registry and research platform dedicated to renal cancer. Funded by the French National Cancer Institute (INCa), UroCCR prospectively collects comprehensive real-world data on patient care and disease evolution, while systematically linking these records with annotated biological samples (plasma, urine, and both healthy and tumour tissues). For each case, more than one thousand variables may be recorded, covering clinical, imaging, and patient-reported information.
More than a registry, UroCCR is a collaborative network of clinical and research professionals using a shared, evolving tool that supports rapid implementation of studies and fosters active knowledge generation. Unlike retrospective registries or sample-centred biobanks, UroCCR offers prospective, patient-focused inclusion and a wide scope of investigation-from translational and technological research to clinical evaluation and social sciences. It also supports multiple ancillary studies, including retrospective analyses and prospective clinical or observational trials, and operates under a structured governance system with recognised national and international labels.
By combining a rigorously structured, multicentre dataset with linkage to the French national health data system (SNDS), the platform uniquely unites detailed clinical annotation with population-wide coverage, creating a high-value environment for advancing kidney cancer research and care.
The UroCCR project is a national kidney cancer registry and research network designed to address the specific challenges of renal cell carcinoma (RCC) management. While general cancer registries such as FRANCIM provide valuable surveillance data, most large-scale registries lack the depth of clinical, biological, and longitudinal follow-up information necessary to advance research and enable comprehensive analyses of kidney cancer outcomes. UroCCR was created in 2011 to meet this need.
With over 21,000 cases collected from 58 centres across France, UroCCR is now one of the largest national databases dedicated to kidney cancer worldwide. The registry captures detailed clinical parameters, treatments and outcomes, complemented by patient-reported measures and socioeconomic data. Because management practices within UroCCR follow the recommendations of the French Association of Urology (AFU), the dataset closely reflects real-world practice and provides a reliable basis for comparison with national and European guidelines. Moreover, patient data can be reused across numerous studies, allowing researchers to explore multiple scientific questions without requiring new enrolments for each project.
A distinctive strength of UroCCR is its integration of multiple research dimensions. Beyond clinical outcomes, it evaluates quality of life and the social and economic impact of kidney cancer. The registry is linked to annotated biobanking and national medico-administrative datasets, enabling translational studies and health services research. Additionally, UroCCR supports multiple ancillary studies, both retrospective analyses based on real-world data and prospective studies including randomised clinical trials or observational cohorts.
The project benefits from robust governance structures, ensuring standardised procedures, data quality, and ethical oversight. It has also received various national and international labels, recognising its methodological rigour and excellence in research infrastructure.
Digital innovations developed within the network, such as UroConnect® for perioperative monitoring and UroPredict machine learning models for recurrence and survival prediction, highlight its commitment to advancing care through new technologies.
At the national level, projects such as CARARE are developing personalised treatment strategies, including a molecular tumour board for non-clear cell RCC. Internationally, UroCCR is strengthening collaboration through partnerships with the European Association of Urology and the European Robotic Urology Section, contributing to harmonised data collection and large-scale multicentre research.
Ultimately, UroCCR functions as a dynamic research platform that unites clinicians, researchers, and patients around a shared infrastructure. By combining detailed clinical data with translational research, digital health tools, structured governance, recognised labels, and international partnerships, it aims to generate increasingly precise insights into RCC and to support the development of more effective, personalised treatment strategies in France and worldwide.
Objectives
Allow any data controller who meets the necessary requirements to reuse the data contained therein for the purposes of research, evaluation or the advancement of knowledge in the following subject areas:
1-Descriptive epidemiology of kidney cancer; 2-Pharmaco-epidemiology and treatment monitoring: safety, efficacy, real-world treatment indications, costs; 3 -Quality of life and other 'patient-reported outcomes' and/or 'patient-reported experiences' (which may be collected automatically via digital methods using UroConnect), personal, family, professional and social consequences of kidney cancer; 4-Research into diagnostic, prognostic and predictive biomarkers; 5-Research into markers predictive of disease progression; 6-Evaluation of clinical practices and treatment techniques (surgical, interventional and drug-based) ; 7-Research related to the National Health Data System.
Patients with Kidney cancer
Inclusion Criteria:
Exclusion Criteria: none
Adult patients with kidney cancer
Procedure: Radical nephrectomy versus partial nephrectomy (according surgeon judgement)
Promotion of Prospective Research Projects
Development and conduct of prospective research projects across a broad range of thematic fields related to kidney cancer .
Time frame: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Establishment of a Multicentre Annotated Biological Sample Collection
Annotation of biological samples collection and associated clinical data to support translational and clinical research in kidney cancer.
Time frame: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Advancement of Knowledge in Kidney Cancer Descriptive Epidemiology
Characterization of the incidence, prevalence, distribution, and trends of kidney cancer within the population
Time frame: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Advancement of Knowledge in Pharmacoepidemiology and Treatment Monitoring in Kidney Cancer
Evaluatation of treatment safety, efficacy, real-world indications, utilization patterns, and associated healthcare costs
Time frame: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Advancement of Knowledge in Quality of Life and Patient-Reported Outcomes in Kidney Cancer
Assessment of quality of life, patient-reported outcomes (PROs), and patient-reported experiences (PREs), including the personal, familial, professional, and social impact of kidney cancer. Data may be collected through digital tools such as UroConnect
Time frame: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Diagnostic, Prognostic, and Predictive Biomarker Research
Identification and validation of biomarkers for diagnosis, prognosis, and prediction of treatment response in kidney cancer
Time frame: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Evaluation of Clinical Practices and Treatment Strategies
Assessment of surgical, interventional, and pharmacological treatment approaches to improve clinical practice and patient outcomes.
Time frame: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Research Using National Health Data System Data
Conduct of studies using data from the National Health Data System to support epidemiological, clinical, and health services research
Time frame: From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux